Whatever the somewhat clumsy detail of the license, and wherever the ensueing discussions with funders will lead on the ground, this is excellent news.
Big congratulations to Merck KgA for resurrecting their cladribine programme after BartsMS had started their own given the excellent data produced back in the 90s and 00s, and about which we have been reporting extensively, on this blog and elsewhere.
Here’s a reminder of the positive opinion by the EMA’s CHMP, which now triggered the rubber stamping by the European Commission:
With Ocrevus licensed in the US, waiting to hear from the EMA, and now Mavenclad licensed in Europe, and expected discussions with the FDA, almighty campaigns are underway to treat you as pwMS with these compounds, and for market shares.
BartsMS will try and do their bit to insure you remain top of the agenda, no matter what, and in spite of our own conflicts.
CoI: Multiple, including payments for consultancy & lecturing by Roche and MerckKgA.